CLINICAL TRIALS PROFILE FOR XALATAN
✉ Email this page to a colleague
505(b)(2) Clinical Trials for XALATAN
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT00402493 ↗ | Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops | Completed | Pfizer | N/A | 2006-12-01 | The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops. |
| OTC | NCT00402493 ↗ | Study to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops | Completed | Philadelphia Eye Associates | N/A | 2006-12-01 | The Purpose of This Study is to Determine if Taking an Over the Counter Non-Steroidal Anti-Inflammatory(Ibuprofen)has an Effect on Eye Pressure in Patients using Brimonidine(Alphagan)and Latanoprost(Xalatan) eye drops. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for XALATAN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00140062 ↗ | Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension. | Completed | Pfizer | Phase 4 | 2002-02-01 | The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated. |
| NCT00143429 ↗ | Corneal Versus Conjunctival Delivery Using a Delivery Device | Withdrawn | Pfizer | Phase 2 | 1969-12-31 | Compare the antihypertensive efficacy of three methods for installing Xalatan |
| NCT00143429 ↗ | Corneal Versus Conjunctival Delivery Using a Delivery Device | Withdrawn | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 2 | 1969-12-31 | Compare the antihypertensive efficacy of three methods for installing Xalatan |
| NCT00159653 ↗ | A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma | Completed | Pfizer | Phase 3 | 2005-07-01 | To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12. |
| NCT00159653 ↗ | A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma | Completed | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 3 | 2005-07-01 | To demonstrate statistical superiority of the combination of latanoprost and timolol to the individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8 AM, 10 AM, 4 PM at weeks 2, 6 and 12. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for XALATAN
Condition Name
Clinical Trial Locations for XALATAN
Trials by Country
Clinical Trial Progress for XALATAN
Clinical Trial Phase
Clinical Trial Sponsors for XALATAN
Sponsor Name
